 BOSTON--BUSINESS WIRE--- KRTX--Karuna Therapeutics, Inc. NASDAQ: KRTX, a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2021 and provided a general business update. The second quarter was an exciting one for Karuna as weve made important progress in advancing our mid- and late-stage clinical trials studying our lead asset, KarX 